TITLE

FDA hearings leave doctors, patients in limbo on Avandia

AUTHOR(S)
Eggertson, Laura; Woodward, Cal
PUB. DATE
September 2010
SOURCE
CMAJ: Canadian Medical Association Journal;9/7/2010, Vol. 182 Issue 12, pE559
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the effects of the inquiry made by the U.S. Food and Drug Administration (FDA) on GlaxoSmithKline's Avandia, a drug for type 2 diabetes, to physicians and patients. It relates that the public hearings undertaken by the agency were for the safety profile of rosiglitazone following the call to remove the drug out of the market. It also mentions that the results of the hearings conducted by FDA leave the doctors and patients in a limbo because of contradictory findings.
ACCESSION #
54110651

 

Related Articles

  • Avandia on Trial. Armstrong, Walter // Pharmaceutical Executive;Jul2010, Vol. 30 Issue 7, p90 

    The article reports on the possible fate of Avandia (rosiglitazone) for diabetes from GlaxoSmithKline (GSK) on the decision of the Food and Drug Administration (FDA) in the U.S. It mentions that the FDA will hold a meeting in the middle of July 2010 to decide the fate of Avandia which was found...

  • FDA Panel: Keep Avandia on Market With Restrictions.  // Bioworld Week;7/19/2010, Vol. 18 Issue 29, p1 

    The article reports on the restrictions made by the panel of the U.S. Food and Drug Administration regarding the type II diabetes drug Avandia (rosiglitazone) from GlaxoSmithKline. It mentions the availability of the drug in the U.S. market despite the warnings and limited use related to heart...

  • FDA to take closer look at diabetes drug. O'Connor, John // McKnight's Long-Term Care News;Apr2010, Vol. 31 Issue 4, p24 

    The article reports on the decision of the Food and Drug Administration to examine data and reports on the safety of Avandia, the diabetes drug of GlaxoSmithKline, in the U.S. in 2010.

  • Mixed vote on rosiglitazone. Elliott, William T. // Neurology Alert;Sep2010 Pharmacology, p2 

    The article reports on the mixed vote issued by a U.S. Food and Drug Administration (FDA) committee regarding GlaxoSmithKline's rosiglitazone drug.

  • WEEK IN WASHINGTON.  // BioWorld Insight;9/27/2010, Vol. 18 Issue 39, p6 

    The article reports on the decision of U.S. Food and Drug Administration that GlaxoSmithKline's diabetes drug Avandia or rosiglitazone will stay on the market, but under a tight restricted access program.

  • Mixed vote on rosiglitazone.  // OB/GYN Clinical Alert;Sep2010 Pharmacology, p2 

    The article reports the mixed decisions of the U.S. Food and Drug Administration (FDA) on the withdrawal of the diabetes drug rosiglitazone by GlaxoSmithKline.

  • Panel Says Avandia Should Stay.  // Chain Drug Review;8/30/2010, Vol. 32 Issue 14, p30 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to continue the marketing of the antidiabetic drug Avadia from GlaxoSmithKline despite evidence that the drug increases the risk of heart attack.

  • FDA Panel: Keep Avandia on Market With Restrictions. Young, Donna // BioWorld Today;7/15/2010, Vol. 21 Issue 135, p1 

    The article reports on the decision of a U.S. Food and Drug Administration (FDA) panel to restrict the use of the Type II diabetes drug Avandia (rosiglitazone) in the U.S. market. The panel also warned on possible heart attacks among patients taking the drug, which is manufactured by...

  • Mixed vote on rosiglitazone. Elliot, William T. // Infectious Disease Alert;Sep2010 Supplement, p2 

    The article reports on the mixed vote result of the U.S. Food and Drug Administration (FDA) committee on the embattled diabetes drug rosiglitazone, brand name Avandia by GlaxoSmithKline, which has been under heavy scrutiny since 2007 when a study from the Cleveland Clinic linked the drug to an...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics